group_name,group_level,strata_name,strata_level,window_name,variable,variable_type,variable_level,estimate_type,estimate,cdm_name,generated_by
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Accidental poisoning by and exposure to noxious substances [X40-X49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Delivery [O80-O84],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,denominator,binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Acute rheumatic fever [I00-I02],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Renal failure [N17-N19],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Renal failure [N17-N19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Hernia [K40-K46],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of appendix [K35-K38],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Mycoses [B35-B49],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Falls [W00-W19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Infections specific to the perinatal period [P35-P39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Contact with heat and hot substances [X10-X19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Hernia [K40-K46],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasms of female genital organs [C51-C58],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Falls [W00-W19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,denominator,binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-Inf to -1,Mycoses [B35-B49],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Infections specific to the perinatal period [P35-P39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Falls [W00-W19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Falls [W00-W19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Hernia [K40-K46],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Acute rheumatic fever [I00-I02],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Mycoses [B35-B49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Mycoses [B35-B49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Mycoses [B35-B49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Renal failure [N17-N19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasms of female genital organs [C51-C58],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Delivery [O80-O84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Hernia [K40-K46],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Hernia [K40-K46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Hernia [K40-K46],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diseases of appendix [K35-K38],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Mycoses [B35-B49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Delivery [O80-O84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Renal failure [N17-N19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Renal failure [N17-N19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Falls [W00-W19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,denominator,binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Falls [W00-W19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Accidental poisoning by and exposure to noxious substances [X40-X49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Contact with heat and hot substances [X10-X19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Mycoses [B35-B49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-Inf to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Mycoses [B35-B49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Mycoses [B35-B49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Hernia [K40-K46],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Accidental poisoning by and exposure to noxious substances [X40-X49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Infections specific to the perinatal period [P35-P39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Malignant neoplasms of female genital organs [C51-C58],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Renal failure [N17-N19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diseases of appendix [K35-K38],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the thorax [S20-S29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,denominator,binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Mycoses [B35-B49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,denominator,binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Mycoses [B35-B49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Acute rheumatic fever [I00-I02],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Delivery [O80-O84],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,denominator,binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,In situ neoplasms [D00-D09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Hernia [K40-K46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of muscles [M60-M63],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other bacterial diseases [A30-A49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Mycoses [B35-B49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Renal failure [N17-N19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Hypertensive diseases [I10-I15],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Papulosquamous disorders [L40-L45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the head [S00-S09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of psychological development [F80-F89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasms of female genital organs [C51-C58],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Falls [W00-W19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Mood [affective] disorders [F30-F39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Hernia [K40-K46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,General symptoms and signs [R50-R69],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Hernia [K40-K46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Contact with heat and hot substances [X10-X19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Hernia [K40-K46],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Glomerular diseases [N00-N08],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of breast [N60-N64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of external ear [H60-H62],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other dorsopathies [M50-M54],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other congenital malformations [Q80-Q89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Metabolic disorders [E70-E90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Disorders of lens [H25-H28],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other infectious diseases [B99-B99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Benign neoplasms [D10-D36],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Disorders of skin appendages [L60-L75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-Inf to -1,Diseases of male genital organs [N40-N51],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other soft tissue disorders [M70-M79],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other diseases of urinary system [N30-N39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Dermatitis and eczema [L20-L30],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other viral diseases [B25-B34],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-Inf to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,Other diseases of intestines [K55-K64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-Inf to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-Inf to -1,Other joint disorders [M20-M25],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-Inf to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-Inf to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-Inf to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-Inf to -1,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-Inf to -1,Other disorders of ear [H90-H95],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,denominator,binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Acute rheumatic fever [I00-I02],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Glaucoma [H40-H42],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Renal failure [N17-N19],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Hernia [K40-K46],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Mycoses [B35-B49],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Falls [W00-W19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Chondropathies [M91-M94],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Exposure to forces of nature [X30-X39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Glaucoma [H40-H42],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Arthrosis [M15-M19],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Contact with heat and hot substances [X10-X19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Chondropathies [M91-M94],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the thorax [S20-S29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Arthrosis [M15-M19],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Hernia [K40-K46],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Falls [W00-W19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,denominator,binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Mycoses [B35-B49],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Accidental poisoning by and exposure to noxious substances [X40-X49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Arthrosis [M15-M19],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Renal failure [N17-N19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Arthrosis [M15-M19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Acute rheumatic fever [I00-I02],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Arthrosis [M15-M19],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Mycoses [B35-B49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Mycoses [B35-B49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Arthrosis [M15-M19],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Mycoses [B35-B49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Arthrosis [M15-M19],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Renal failure [N17-N19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the thorax [S20-S29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Mycoses [B35-B49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Chondropathies [M91-M94],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Chondropathies [M91-M94],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Chondropathies [M91-M94],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Arthrosis [M15-M19],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Chondropathies [M91-M94],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Mycoses [B35-B49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Renal failure [N17-N19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Renal failure [N17-N19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,denominator,binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Chondropathies [M91-M94],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Accidental poisoning by and exposure to noxious substances [X40-X49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Contact with heat and hot substances [X10-X19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Mycoses [B35-B49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Mycoses [B35-B49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Mycoses [B35-B49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Chondropathies [M91-M94],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Hernia [K40-K46],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Arthrosis [M15-M19],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Accidental poisoning by and exposure to noxious substances [X40-X49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Glaucoma [H40-H42],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Toxic effects of substances chiefly nonmedicinal as to source [T51-T65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Burns and corrosions of external body surface, specified by site [T20-T25]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Glaucoma [H40-H42],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Arthrosis [M15-M19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the thorax [S20-S29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,denominator,binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Mycoses [B35-B49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,denominator,binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other spirochaetal diseases [A65-A69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Arthrosis [M15-M19],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Arthrosis [M15-M19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Acute rheumatic fever [I00-I02],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Chondropathies [M91-M94],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,denominator,binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Arthrosis [M15-M19],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of muscles [M60-M63],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Mycoses [B35-B49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Arthrosis [M15-M19],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Renal failure [N17-N19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Hypertensive diseases [I10-I15],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Demyelinating diseases of the central nervous system [G35-G37],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Chondropathies [M91-M94],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,General symptoms and signs [R50-R69],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Contact with heat and hot substances [X10-X19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Glomerular diseases [N00-N08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diseases of external ear [H60-H62],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other dorsopathies [M50-M54],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Metabolic disorders [E70-E90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Disorders of lens [H25-H28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other infectious diseases [B99-B99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Benign neoplasms [D10-D36],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,Other diseases of intestines [K55-K64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,Other joint disorders [M20-M25],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,Other disorders of ear [H90-H95],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,denominator,binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Renal failure [N17-N19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Renal failure [N17-N19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Mycoses [B35-B49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Chondropathies [M91-M94],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Arthrosis [M15-M19],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Arthrosis [M15-M19],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,denominator,binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Mycoses [B35-B49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Arthrosis [M15-M19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Renal failure [N17-N19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Mycoses [B35-B49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Renal failure [N17-N19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Arthrosis [M15-M19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,denominator,binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Arthrosis [M15-M19],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Arthrosis [M15-M19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Arthrosis [M15-M19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,denominator,binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,denominator,binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Arthrosis [M15-M19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,denominator,binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Arthrosis [M15-M19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Renal failure [N17-N19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Arthrosis [M15-M19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Renal failure [N17-N19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of lens [H25-H28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Pediculosis, acariasis and other infestations [B85-B89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Noninfective enteritis and colitis [K50-K52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Disorders of other endocrine glands [E20-E35],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Renal failure [N17-N19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Hypertensive diseases [I10-I15],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Unspecified mental disorder [F99-F99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Diabetes mellitus [E10-E14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of muscles [M60-M63],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,General symptoms and signs [R50-R69],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Acute upper respiratory infections [J00-J06],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Glomerular diseases [N00-N08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Systemic connective tissue disorders [M30-M36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Chronic lower respiratory diseases [J40-J47],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other disorders of kidney and ureter [N25-N29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other diseases of the digestive system [K90-K93],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Obesity and other hyperalimentation [E65-E68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other infectious diseases [B99-B99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other osteopathies [M86-M90],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other soft tissue disorders [M70-M79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Cerebrovascular diseases [I60-I69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Dermatitis and eczema [L20-L30],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,Disorders of synovium and tendon [M65-M68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Other diseases of intestines [K55-K64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,Other joint disorders [M20-M25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Benign neoplasms [D10-D36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Spondylopathies [M45-M49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,denominator,binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other joint disorders [M20-M25],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other and unspecified effects of external causes [T66-T78],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other osteopathies [M86-M90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Arthrosis [M15-M19],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other osteopathies [M86-M90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,denominator,binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Other joint disorders [M20-M25],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Unspecified mental disorder [F99-F99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Arthrosis [M15-M19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other joint disorders [M20-M25],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other viral diseases [B25-B34],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other joint disorders [M20-M25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Arthrosis [M15-M19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Arthrosis [M15-M19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other joint disorders [M20-M25],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other joint disorders [M20-M25],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,denominator,binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other joint disorders [M20-M25],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Arthrosis [M15-M19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Other joint disorders [M20-M25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Arthrosis [M15-M19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Other osteopathies [M86-M90],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Arthrosis [M15-M19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Other viral diseases [B25-B34],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Infectious arthropathies [M00-M03],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other joint disorders [M20-M25],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Bullous disorders [L10-L14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other joint disorders [M20-M25],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Systemic connective tissue disorders [M30-M36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,General symptoms and signs [R50-R69],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other joint disorders [M20-M25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,denominator,binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other joint disorders [M20-M25],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other joint disorders [M20-M25],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Arthrosis [M15-M19],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Inflammatory polyarthropathies [M05-M14],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Disorders of synovium and tendon [M65-M68],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,Metabolic disorders [E70-E90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,Dermatitis and eczema [L20-L30],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Cerebrovascular diseases [I60-I69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Spondylopathies [M45-M49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,denominator,binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Diseases of liver [K70-K77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of lens [H25-H28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Renal failure [N17-N19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of skin appendages [L60-L75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Arthrosis [M15-M19],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other joint disorders [M20-M25],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of lens [H25-H28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other osteopathies [M86-M90],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Arthrosis [M15-M19],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other viral diseases [B25-B34],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other osteopathies [M86-M90],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,denominator,binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Spondylopathies [M45-M49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other joint disorders [M20-M25],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of lens [H25-H28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other osteopathies [M86-M90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Arthrosis [M15-M19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other joint disorders [M20-M25],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of skin appendages [L60-L75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Arthrosis [M15-M19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other osteopathies [M86-M90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other joint disorders [M20-M25],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other viral diseases [B25-B34],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other viral diseases [B25-B34],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Arthrosis [M15-M19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Arthrosis [M15-M19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other joint disorders [M20-M25],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,denominator,binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other joint disorders [M20-M25],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other viral diseases [B25-B34],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other viral diseases [B25-B34],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other viral diseases [B25-B34],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other osteopathies [M86-M90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of lens [H25-H28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of skin appendages [L60-L75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other joint disorders [M20-M25],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,denominator,binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other joint disorders [M20-M25],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Arthrosis [M15-M19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Arthrosis [M15-M19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Arthrosis [M15-M19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Injuries involving multiple body regions [T00-T07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other joint disorders [M20-M25],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Deforming dorsopathies [M40-M43],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of thyroid gland [E00-E07],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other diseases of the digestive system [K90-K93],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Arthrosis [M15-M19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Spondylopathies [M45-M49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Noninfective enteritis and colitis [K50-K52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of other endocrine glands [E20-E35],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Inflammatory polyarthropathies [M05-M14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Hypertensive diseases [I10-I15],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Unspecified mental disorder [F99-F99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Diseases of liver [K70-K77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,General symptoms and signs [R50-R69],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other disorders of the genitourinary system [N99-N99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other joint disorders [M20-M25],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other disorders of kidney and ureter [N25-N29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other nutritional deficiencies [E50-E64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Disorders of lens [H25-H28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Obesity and other hyperalimentation [E65-E68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other infectious diseases [B99-B99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other osteopathies [M86-M90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Other disorders of eye and adnexa [H55-H59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other soft tissue disorders [M70-M79],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other diseases of urinary system [N30-N39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Cerebrovascular diseases [I60-I69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Dermatitis and eczema [L20-L30],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,Disorders of synovium and tendon [M65-M68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,Other dorsopathies [M50-M54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Other diseases of intestines [K55-K64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,Other joint disorders [M20-M25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Benign neoplasms [D10-D36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,Other disorders of ear [H90-H95],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Delivery [O80-O84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the head [S00-S09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Spondylopathies [M45-M49],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,denominator,binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Glaucoma [H40-H42],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of lens [H25-H28],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Renal failure [N17-N19],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Renal failure [N17-N19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of peritoneum [K65-K67],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Hernia [K40-K46],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Mycoses [B35-B49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Falls [W00-W19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Suppurative and necrotic conditions of lower respiratory tract [J85-J86],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Exposure to animate mechanical forces [W50-W64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Chondropathies [M91-M94],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Exposure to forces of nature [X30-X39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Glaucoma [H40-H42],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Malnutrition [E40-E46],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Diseases of liver [K70-K77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Infectious arthropathies [M00-M03],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Arthrosis [M15-M19],binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the head [S00-S09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Tuberculosis [A15-A19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other joint disorders [M20-M25],binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other viral diseases [B25-B34],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Chondropathies [M91-M94],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of lens [H25-H28],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other osteopathies [M86-M90],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Arthrosis [M15-M19],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other viral diseases [B25-B34],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other osteopathies [M86-M90],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Hernia [K40-K46],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Falls [W00-W19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,denominator,binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Spondylopathies [M45-M49],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Mycoses [B35-B49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Other joint disorders [M20-M25],binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Falls [W00-W19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of lens [H25-H28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Arthrosis [M15-M19],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of lens [H25-H28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other joint disorders [M20-M25],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Arthrosis [M15-M19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other osteopathies [M86-M90],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Arthrosis [M15-M19],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other osteopathies [M86-M90],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other joint disorders [M20-M25],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other viral diseases [B25-B34],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Mycoses [B35-B49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other viral diseases [B25-B34],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Arthrosis [M15-M19],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other joint disorders [M20-M25],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Mycoses [B35-B49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other viral diseases [B25-B34],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diseases of liver [K70-K77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Spondylopathies [M45-M49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Suppurative and necrotic conditions of lower respiratory tract [J85-J86],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Arthrosis [M15-M19],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Spondylopathies [M45-M49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other joint disorders [M20-M25],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other osteopathies [M86-M90],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Glaucoma [H40-H42],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of lens [H25-H28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other joint disorders [M20-M25],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Chondropathies [M91-M94],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other osteopathies [M86-M90],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of lens [H25-H28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Arthrosis [M15-M19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Mycoses [B35-B49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Renal failure [N17-N19],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Spondylopathies [M45-M49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of lens [H25-H28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Exposure to forces of nature [X30-X39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other osteopathies [M86-M90],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Tuberculosis [A15-A19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Spondylopathies [M45-M49],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the head [S00-S09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other viral diseases [B25-B34],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,denominator,binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Spondylopathies [M45-M49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other joint disorders [M20-M25],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Disorders of lens [H25-H28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other viral diseases [B25-B34],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Hernia [K40-K46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Spondylopathies [M45-M49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other osteopathies [M86-M90],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other osteopathies [M86-M90],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of lens [H25-H28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the head [S00-S09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Falls [W00-W19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Diseases of liver [K70-K77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Hernia [K40-K46],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Renal failure [N17-N19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Arthrosis [M15-M19],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other joint disorders [M20-M25],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other osteopathies [M86-M90],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Spondylopathies [M45-M49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Spondylopathies [M45-M49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Renal failure [N17-N19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other joint disorders [M20-M25],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other osteopathies [M86-M90],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Tuberculosis [A15-A19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other viral diseases [B25-B34],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Arthrosis [M15-M19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other viral diseases [B25-B34],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Mycoses [B35-B49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other viral diseases [B25-B34],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other joint disorders [M20-M25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other acute lower respiratory infections [J20-J22],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Arthrosis [M15-M19],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Arthrosis [M15-M19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other joint disorders [M20-M25],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other joint disorders [M20-M25],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,denominator,binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other joint disorders [M20-M25],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Arthrosis [M15-M19],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other bacterial diseases [A30-A49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Mycoses [B35-B49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Chronic lower respiratory diseases [J40-J47],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Arthrosis [M15-M19],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of other endocrine glands [E20-E35],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of lens [H25-H28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Hypertensive diseases [I10-I15],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Spondylopathies [M45-M49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other nutritional deficiencies [E50-E64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Lung diseases due to external agents [J60-J70],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other viral diseases [B25-B34],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other diseases of the respiratory system [J95-J99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Systemic connective tissue disorders [M30-M36],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of lens [H25-H28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of lens [H25-H28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Suppurative and necrotic conditions of lower respiratory tract [J85-J86],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other osteopathies [M86-M90],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of inner ear [H80-H83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Arthrosis [M15-M19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other disorders of the genitourinary system [N99-N99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Noninfective enteritis and colitis [K50-K52],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Mood [affective] disorders [F30-F39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Inflammatory polyarthropathies [M05-M14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Chondropathies [M91-M94],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other viral diseases [B25-B34],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Unspecified mental disorder [F99-F99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Injuries involving multiple body regions [T00-T07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,General symptoms and signs [R50-R69],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other forms of heart disease [I30-I52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Acute upper respiratory infections [J00-J06],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Hernia [K40-K46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Intestinal infectious diseases [A00-A09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Glomerular diseases [N00-N08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the elbow and forearm [S50-S59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other dorsopathies [M50-M54],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of conjunctiva [H10-H13],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Injuries to the wrist and hand [S60-S69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Other joint disorders [M20-M25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other and unspecified effects of external causes [T66-T78],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Disorders of choroid and retina [H30-H36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Injuries to the ankle and foot [S90-S99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other disorders of eye and adnexa [H55-H59],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Other diseases of the digestive system [K90-K93],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Metabolic disorders [E70-E90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Disorders of lens [H25-H28],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other infectious diseases [B99-B99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Benign neoplasms [D10-D36],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,Diseases of male genital organs [N40-N51],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other diseases of urinary system [N30-N39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,Cerebrovascular diseases [I60-I69],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Disorders of synovium and tendon [M65-M68],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,Dermatitis and eczema [L20-L30],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,Other diseases of intestines [K55-K64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,Other joint disorders [M20-M25],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,Other disorders of ear [H90-H95],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases caused by chlamydiae [A70-A74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Delivery [O80-O84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,denominator,binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Chromosomal abnormalities, not elsewhere classified [Q90-Q99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Glaucoma [H40-H42],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Renal failure [N17-N19],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Renal failure [N17-N19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of peritoneum [K65-K67],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Hernia [K40-K46],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Urolithiasis [N20-N23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Chromosomal abnormalities, not elsewhere classified [Q90-Q99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Mycoses [B35-B49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Falls [W00-W19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Suppurative and necrotic conditions of lower respiratory tract [J85-J86],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Chondropathies [M91-M94],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Exposure to forces of nature [X30-X39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Glaucoma [H40-H42],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Malnutrition [E40-E46],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Infectious arthropathies [M00-M03],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Arthrosis [M15-M19],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Tuberculosis [A15-A19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Chondropathies [M91-M94],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Arthrosis [M15-M19],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malnutrition [E40-E46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Hernia [K40-K46],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasms of female genital organs [C51-C58],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Falls [W00-W19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other diseases caused by chlamydiae [A70-A74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,denominator,binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Mental retardation [F70-F79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Infections specific to the perinatal period [P35-P39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Mycoses [B35-B49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Falls [W00-W19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Arthrosis [M15-M19],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Renal failure [N17-N19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Glaucoma [H40-H42],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Arthrosis [M15-M19],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases caused by chlamydiae [A70-A74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Malnutrition [E40-E46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Arthrosis [M15-M19],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Mycoses [B35-B49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Arthrosis [M15-M19],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Infections specific to the perinatal period [P35-P39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Mycoses [B35-B49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Suppurative and necrotic conditions of lower respiratory tract [J85-J86],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Arthrosis [M15-M19],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Renal failure [N17-N19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of female genital organs [C51-C58],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Chromosomal abnormalities, not elsewhere classified [Q90-Q99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Malnutrition [E40-E46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Chondropathies [M91-M94],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Chondropathies [M91-M94],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Glaucoma [H40-H42],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Arthrosis [M15-M19],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Hernia [K40-K46],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Urolithiasis [N20-N23],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Chondropathies [M91-M94],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Chromosomal abnormalities, not elsewhere classified [Q90-Q99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Renal failure [N17-N19],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Falls [W00-W19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Exposure to forces of nature [X30-X39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Tuberculosis [A15-A19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Chondropathies [M91-M94],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases caused by chlamydiae [A70-A74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Glaucoma [H40-H42],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,denominator,binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Mycoses [B35-B49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Hernia [K40-K46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Mycoses [B35-B49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Chondropathies [M91-M94],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Hernia [K40-K46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Chondropathies [M91-M94],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Infections with a predominantly sexual mode of transmission [A50-A64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Falls [W00-W19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Hernia [K40-K46],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Renal failure [N17-N19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Arthrosis [M15-M19],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Renal failure [N17-N19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Arthrosis [M15-M19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Medical devices associated with adverse incidents in diagnostic and therapeutic use [Y70-Y82],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases caused by chlamydiae [A70-A74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Glaucoma [H40-H42],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Malignant neoplasms of lip, oral cavity and pharynx [C00-C14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Exposure to electric current, radiation and extreme ambient air temperature and pressure [W85-W99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Chromosomal abnormalities, not elsewhere classified [Q90-Q99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Renal failure [N17-N19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue [C81-C96]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Congenital malformations of eye, ear, face and neck [Q10-Q18]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Renal failure [N17-N19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasm of breast [C50-C50],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other respiratory diseases principally affecting the interstitium [J80-J84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Mycoses [B35-B49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Mental and behavioural disorders due to psychoactive substance use [F10-F19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Chondropathies [M91-M94],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Tuberculosis [A15-A19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Sequelae of infectious and parasitic diseases [B90-B94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Mental retardation [F70-F79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Chromosomal abnormalities, not elsewhere classified [Q90-Q99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Chondropathies [M91-M94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Mental retardation [F70-F79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Exposure to animate mechanical forces [W50-W64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Complications predominantly related to the puerperium [O85-O92],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Neoplasms of uncertain or unknown behaviour [D37-D48],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Other obstetric conditions, not elsewhere classified [O94-O99]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Inflammatory diseases of the central nervous system [G00-G09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Glaucoma [H40-H42],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Infectious arthropathies [M00-M03],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Arthrosis [M15-M19],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the thorax [S20-S29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Mycoses [B35-B49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasms of urinary tract [C64-C68],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Malnutrition [E40-E46],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Burns and corrosions of multiple and unspecified body regions [T29-T32],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Melanoma and other malignant neoplasms of skin [C43-C44],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Effects of foreign body entering through natural orifice [T15-T19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,denominator,binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on examination of urine, without diagnosis [R80-R82]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Falls [W00-W19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other spirochaetal diseases [A65-A69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Exposure to forces of nature [X30-X39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Behavioural and emotional disorders with onset usually occurring in childhood and adolescence [F90-F98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases caused by chlamydiae [A70-A74],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of optic nerve and visual pathways [H46-H48],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Arthrosis [M15-M19],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Disorders of eyelid, lacrimal system and orbit [H00-H06]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Arthrosis [M15-M19],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Urolithiasis [N20-N23],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Chondropathies [M91-M94],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other congenital malformations of the digestive system [Q38-Q45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Injuries to the abdomen, lower back, lumbar spine and pelvis [S30-S39]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Accidental exposure to other and unspecified factors [X58-X59],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other acute lower respiratory infections [J20-J22],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving speech and voice [R47-R49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Glaucoma [H40-H42],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other maternal disorders predominantly related to pregnancy [O20-O29],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,denominator,binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Diseases of liver [K70-K77],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Deforming dorsopathies [M40-M43],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Arthrosis [M15-M19],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Persons with potential health hazards related to communicable diseases [Z20-Z29],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,In situ neoplasms [D00-D09],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of bone density and structure [M80-M85],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Malignant neoplasms of eye, brain and other parts of central nervous system [C69-C72]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of muscles [M60-M63],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other bacterial diseases [A30-A49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the shoulder and upper arm [S40-S49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Malignant neoplasms of digestive organs [C15-C26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Mycoses [B35-B49],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Infections of the skin and subcutaneous tissue [L00-L08],binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other disorders of the musculoskeletal system and connective tissue [M95-M99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Infectious arthropathies [M00-M03],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Chronic lower respiratory diseases [J40-J47],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Renal tubulo-interstitial diseases [N10-N16],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Arthrosis [M15-M19],binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Congenital malformations of the respiratory system [Q30-Q34],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of other endocrine glands [E20-E35],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Exposure to smoke, fire and flames [X00-X09]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Renal failure [N17-N19],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Arthropod-borne viral fevers and viral haemorrhagic fevers [A92-A99],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Hypertensive diseases [I10-I15],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other nutritional deficiencies [E50-E64],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Abnormal findings on diagnostic imaging and in function studies, without diagnosis [R90-R94]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Renal failure [N17-N19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the skin and subcutaneous tissue [R20-R23],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Lung diseases due to external agents [J60-J70],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Papulosquamous disorders [L40-L45],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other disorders of kidney and ureter [N25-N29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other diseases of the respiratory system [J95-J99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Cerebral palsy and other paralytic syndromes [G80-G83],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the head [S00-S09],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Systemic connective tissue disorders [M30-M36],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Malnutrition [E40-E46],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Diabetes mellitus [E10-E14],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Complications of labour and delivery [O60-O75],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Persons encountering health services for specific procedures and health care [Z40-Z54],binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of psychological development [F80-F89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Disorders of ocular muscles, binocular movement, accommodation and refraction [H49-H52]",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Malignant neoplasms of male genital organs [C60-C63],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Poisoning by drugs, medicaments and biological substances [T36-T50]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Disorders of gallbladder, biliary tract and pancreas [K80-K87]",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasms of female genital organs [C51-C58],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Bacterial, viral and other infectious agents [B95-B98]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Ischaemic heart diseases [I20-I25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Suppurative and necrotic conditions of lower respiratory tract [J85-J86],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diseases of peritoneum [K65-K67],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Falls [W00-W19],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Certain zoonotic bacterial diseases [A20-A28],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of inner ear [H80-H83],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malnutrition [E40-E46],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Visual disturbances and blindness [H53-H54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Arthrosis [M15-M19],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other disorders of the genitourinary system [N99-N99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Noninfective enteritis and colitis [K50-K52],binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Disorders of sclera, cornea, iris and ciliary body [H15-H22]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Mood [affective] disorders [F30-F39],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Persons encountering health services in circumstances related to reproduction [Z30-Z39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Sequelae of injuries, of poisoning and of other consequences of external causes [T90-T98]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Extrapyramidal and movement disorders [G20-G26],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the circulatory and respiratory systems [R00-R09],binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Inflammatory polyarthropathies [M05-M14],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Diseases of middle ear and mastoid [H65-H75],binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Glaucoma [H40-H42],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Chondropathies [M91-M94],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other viral diseases [B25-B34],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Congenital malformations of the urinary system [Q60-Q64],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of adult personality and behaviour [F60-F69],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Persons encountering health services in other circumstances [Z70-Z76],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Polyneuropathies and other disorders of the peripheral nervous system [G60-G64],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Diseases of myoneural junction and muscle [G70-G73],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Falls [W00-W19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Nerve, nerve root and plexus disorders [G50-G59]",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Maternal care related to the fetus and amniotic cavity and possible delivery problems [O30-O48],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Malignant neoplasms of mesothelial and soft tissue [C45-C49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Radiation-related disorders of the skin and subcutaneous tissue [L55-L59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Unspecified mental disorder [F99-F99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other and unspecified disorders of the circulatory system [I95-I99],binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on examination of blood, without diagnosis [R70-R79]",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Congenital malformations and deformations of the musculoskeletal system [Q65-Q79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Pregnancy with abortive outcome [O00-O08],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries involving multiple body regions [T00-T07],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Inflammatory diseases of female pelvic organs [N70-N77],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,General symptoms and signs [R50-R69],binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Certain disorders involving the immune mechanism [D80-D89],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Organic, including symptomatic, mental disorders [F00-F09]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Persons with potential health hazards related to family and personal history and certain conditions influencing health status [Z80-Z99],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Symptoms and signs involving the digestive system and abdomen [R10-R19],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Urticaria and erythema [L50-L54],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other forms of heart disease [I30-I52],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Acute upper respiratory infections [J00-J06],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Spondylopathies [M45-M49],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Episodic and paroxysmal disorders [G40-G47],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Hernia [K40-K46],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Persons with potential health hazards related to socioeconomic and psychosocial circumstances [Z55-Z65],binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Intestinal infectious diseases [A00-A09],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Persons encountering health services for examination and investigation [Z00-Z13],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Transitory endocrine and metabolic disorders specific to fetus and newborn [P70-P74],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Chondropathies [M91-M94],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other diseases of blood and blood-forming organs [D70-D77],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Glomerular diseases [N00-N08],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other diseases of upper respiratory tract [J30-J39],binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,"Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium [O10-O16]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of breast [N60-N64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,"Symptoms and signs involving cognition, perception, emotional state and behaviour [R40-R46]",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Influenza and pneumonia [J09-J18],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the neck [S10-S19],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Complications of surgical and medical care, not elsewhere classified [T80-T88]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Provisional assignment of new diseases of uncertain etiology or emergency use [U00-U49],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Coagulation defects, purpura and other haemorrhagic conditions [D65-D69]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Congenital malformations of the circulatory system [Q20-Q28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Diseases of external ear [H60-H62],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Pulmonary heart disease and diseases of pulmonary circulation [I26-I28],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the elbow and forearm [S50-S59],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of appendix [K35-K38],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Obesity and other hyperalimentation [E65-E68],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other dorsopathies [M50-M54],binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of conjunctiva [H10-H13],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the wrist and hand [S60-S69],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Malignant neoplasms of bone and articular cartilage [C40-C41],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Adverse effects in the therapeutic use of drugs, medicaments and biological substances causing adverse effects in therapeutic use [Y40-Y59]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,"Neurotic, stress-related and somatoform disorders [F40-F48]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Sequelae of external causes of morbidity and mortality [Y85-Y89],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Injuries to the hip and thigh [S70-S79],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other and unspecified effects of external causes [T66-T78],binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Chronic rheumatic heart diseases [I05-I09],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Infections specific to the perinatal period [P35-P39],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other congenital malformations [Q80-Q89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Disorders of choroid and retina [H30-H36],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Symptoms and signs involving the urinary system [R30-R39],binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Injuries to the ankle and foot [S90-S99],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis [R83-R89]",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other disorders of eye and adnexa [H55-H59],binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other degenerative diseases of the nervous system [G30-G32],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,"Injuries to unspecified part of trunk, limb or body region [T08-T14]",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Other diseases of the digestive system [K90-K93],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Viral infections characterized by skin and mucous membrane lesions [B00-B09],binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Behavioural syndromes associated with physiological disturbances and physical factors [F50-F59],binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of thyroid gland [E00-E07],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Malignant neoplasms of respiratory and intrathoracic organs [C30-C39],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Metabolic disorders [E70-E90],binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,"Diseases of oesophagus, stomach and duodenum [K20-K31]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Disorders of lens [H25-H28],binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other infectious diseases [B99-B99],binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Malignant neoplasms of ill-defined, secondary and unspecified sites [C76-C80]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Benign neoplasms [D10-D36],binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Disorders of skin appendages [L60-L75],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to Inf,Diseases of male genital organs [N40-N51],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Disorders of vitreous body and globe [H43-H45],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Symptoms and signs involving the nervous and musculoskeletal systems [R25-R29],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Nutritional anaemias [D50-D53],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other disorders of the skin and subcutaneous tissue [L80-L99],binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other soft tissue disorders [M70-M79],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other diseases of urinary system [N30-N39],binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,Cerebrovascular diseases [I60-I69],binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Aplastic and other anaemias [D60-D64],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Disorders of synovium and tendon [M65-M68],binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Other diseases of pleura [J90-J94],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to Inf,Dermatitis and eczema [L20-L30],binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Injuries to the knee and lower leg [S80-S89],binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to Inf,Other osteopathies [M86-M90],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,Other diseases of intestines [K55-K64],binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Other disorders of the nervous system [G90-G99],binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Motorcycle rider injured in transport accident [V20-V29],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,"Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified [I80-I89]",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to Inf,Other joint disorders [M20-M25],binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to Inf,Exposure to inanimate mechanical forces [W20-W49],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to Inf,"Diseases of oral cavity, salivary glands and jaws [K00-K14]",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Delivery [O80-O84],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to Inf,"Diseases of arteries, arterioles and capillaries [I70-I79]",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to Inf,Noninflammatory disorders of female genital tract [N80-N98],binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to Inf,Other disorders of ear [H90-H95],binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
